Skip to content

MRI fusion prostate biopsy

The three ways to guide the needle with MRI and what the studies compare.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 16, 2026
Book a consultation
Drawing of the prostate seen from above on MRI, in shades of grey, linked by a dashed line to the ultrasound fan, with the lesion marked by a target
On this page

Quick answer

In a fusion biopsy, the lesion seen on the MRI is located on the ultrasound during the test, and the needle is aimed at it. There are three ways of doing this: cognitive fusion, software fusion and biopsy inside the MRI scanner. The European guideline accepts all three and does not single out one as better.1 In my service, fusion is cognitive, through the transperineal route and with sedation.

What an MRI-guided biopsy is

For a long time, prostate biopsy was guided by ultrasound alone, with cores spread across the whole gland. Today, the MRI comes first. It shows where the suspicious area is, and the biopsy aims at that spot.1

In the PRECISION trial, in men who had never had a biopsy, the strategy with MRI and sampling of the lesion found significant cancer in 38%, against 26% with systematic biopsy. Low-risk cancer, which usually does not need treatment, was found in 9% and 22%.2

In cognitive and software fusion, the ultrasound probe sits in the rectum and shows the prostate in real time. Fusion is the way to bring the MRI information onto that ultrasound. The needle can go in through the perineum, as in a transperineal biopsy, or through the rectum.

The three types of fusion

MethodHow the needle reaches the lesion
Cognitive fusionThe doctor studies the MRI beforehand and, during the ultrasound, finds the lesion by the position it occupies in the prostate5
Software fusionSoftware on the ultrasound machine overlays the MRI images on the ultrasound and marks the lesion on the screen5
In-bore MRI biopsyThe biopsy is done with the patient inside the MRI scanner, guided by images taken at the time3,8

All three are in the European guideline as valid options.1 The choice depends on where the biopsy is done, whether the software or the scanner is available, and the team's experience.4,7

What the studies show

Most studies that compared the methods with each other found similar results for significant cancer:

StudyWhat it comparedSignificant cancer detected
FUTURE, 2019
234 men
All three methods, in men with a previous negative biopsy34% with software, 33% with cognitive and 33% in-bore
2025 review
20 studies, 4,928 men
All three methods39% with software, 37% with cognitive and 47% in-bore, with no statistical difference
IMAGINATION, 2026
648 men
Cognitive and software, almost all without a previous biopsy34% with software and 32% with cognitive

FUTURE, a randomized trial from the Netherlands, found no difference between the three methods, but few men had a lesion on the MRI, which limits the conclusion.3 In IMAGINATION, a randomized trial carried out in China, cognitive fusion was not inferior to software fusion. Weight, however, changed the result. Cognitive fusion had its best results in men with a body mass index below 24, and the software detected more in men at 24 or above. The authors advise caution when applying this cutoff outside Asia.6

Not all studies point the same way. A review done for the British health system concluded that software may detect more significant cancer than cognitive fusion, but the studies were at high risk of bias.5 An older review found more cancer overall with in-bore biopsy than with cognitive fusion, with no difference for significant cancer.8 For the transperineal route, a review of eight studies found similar detection with cognitive and software fusion.7

Operator experience and MRI quality

According to the European guideline, the accuracy of MRI-targeted biopsy depends heavily on the experience of the person performing it, and it improves with practice.1

The MRI also has to be good. The guideline recommends following the PI-RADS rules to perform and read the scan. It mentions a scale to assess image quality, PI-QUAL, and says that MRI performs better with experienced radiologists and at high-volume centers.1 In my practice, if the MRI is of very poor quality, I suggest repeating it before the biopsy.

How many cores are taken

For the lesion, the European guideline calls for at least 3 to 5 cores. When the lesion is PI-RADS 4 or 5, it suggests also sampling the tissue around it, which improves the detection of significant cancer compared with sampling the lesion alone.1

A systematic biopsy, which covers the prostate from base to apex on both sides, uses about 12 cores. Adding systematic biopsy to lesion sampling is the combination that finds the most significant cancer, but it also finds more low-risk cancer.1 In men who have never had a biopsy, leaving out the systematic biopsy would miss about 16% of significant cancers.1

The cores go to the pathologist, and the report shows whether there is cancer and how aggressive it is.

How I approach it

In my practice, I ask for an MRI before recommending a biopsy. With PI-RADS 3 or higher, I recommend the biopsy. Software fusion and cognitive fusion both exist, and the choice depends on where the biopsy is done and whether the software is available. In the service where I work, fusion is cognitive.

I have performed transperineal biopsy since 2022. The test is done in the operating room, always with sedation, and takes about 20 minutes. I take samples from the lesion seen on the MRI and from the rest of the prostate. You go home the same day, with a companion, and should not drive that day.

The first consultation and the results consultation can be in person, at my office in Vila Mariana, or online. My medical license is valid only in Brazil, so I do not issue prescriptions, test orders or medical certificates for use outside Brazil. Preparation and risks are covered in preparing for a prostate biopsy and prostate biopsy complications.

When to see a urologist

  • If your MRI shows PI-RADS 3, 4 or 5
  • If you have been offered a fusion biopsy and want to understand the options
  • If you have had a negative biopsy and the suspicion remains
  • If your PSA or rectal exam is abnormal

Frequently asked questions

What is a fusion biopsy?

It is a biopsy guided by the MRI images. The lesion seen on the MRI is located on the ultrasound during the test, and the needle is aimed at it. The European guideline accepts three ways of doing this, cognitive fusion, software fusion and biopsy inside the MRI scanner.1

Cognitive or software fusion: which one detects more?

In most comparative studies, detection of significant cancer was similar.3,4,7 In a 2026 randomized trial, cognitive fusion was not inferior to software fusion, but the software did better in heavier men.6 A British review found a signal of higher detection with software, based on studies at high risk of bias.5 The European guideline does not single out one method as better.1

Does a fusion biopsy replace a standard biopsy?

It adds to it. Sampling guided by the MRI finds more significant cancer and less low-risk cancer than systematic biopsy alone.1,2 Also sampling the rest of the prostate increases the detection of significant cancer, but also of low-risk cancer.1 In my practice, I take samples from the lesion and from the rest of the prostate.

How many cores are taken?

The European guideline calls for at least 3 to 5 cores from each lesion and suggests also sampling the tissue around it when the lesion is PI-RADS 4 or 5. A systematic biopsy uses about 12 cores.1

Do Brazilian health plans cover fusion biopsy?

In my experience, not yet. Health plans have covered only the transrectal route. The details are in [prostate biopsy cost and insurance](/en/prostate-cancer/biopsy-cost-and-insurance/). If you have insurance from outside Brazil, ask your insurer before you travel.

Does the experience of the person doing the biopsy matter?

Yes. The European guideline says that the accuracy of MRI-targeted biopsy depends heavily on the experience of the person performing it, and that MRI performs better with experienced radiologists.1

Who performs MRI fusion prostate biopsy in São Paulo?

I perform transperineal prostate biopsy with MRI fusion in São Paulo. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. I have performed transperineal biopsy since 2022, always with sedation. My office is in Vila Mariana, and the first consultation can be in person or online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. EAU
  2. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-1777. PubMed
  3. Wegelin O, Exterkate L, van der Leest M, et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582-590. PubMed
  4. Falagario UG, Pellegrino F, Fanelli A, et al. Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies. Prostate Cancer Prostatic Dis. 2025;28(2):270-279. PubMed
  5. Llewellyn A, Phung TH, Soares MO, et al. MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2024;28(61):1-310. PubMed
  6. He BM, Zhang K, Zhou Z, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. 2026;90(5):493-502. PubMed
  7. Pirola GM, Castellani D, Orecchia L, et al. Transperineal US-MRI Fusion-Guided Biopsy for the Detection of Clinical Significant Prostate Cancer: A Systematic Review and Meta-Analysis Comparing Cognitive and Software-Assisted Technique. Cancers (Basel). 2023;15(13):3443. PubMed
  8. Wegelin O, van Melick HHE, Hooft L, et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? Eur Urol. 2017;71(4):517-531. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides